Pyranocoumarins: A new class of anti-hyperglycemic and anti-dyslipidemic agents

被引:142
作者
Kumar, Atul [1 ]
Maurya, Ram Awatar [1 ]
Sharma, Siddharth [1 ]
Ahmad, Pervez [1 ]
Singh, A. B. [2 ]
Bhatia, Gitika [2 ]
Srivastava, Arvind K. [2 ]
机构
[1] Cent Drug Res Inst, Med & Proc Chem Div, Council Sci & Ind Res, Lucknow 226001, Uttar Pradesh, India
[2] Cent Drug Res Inst, Div Biochem, Council Sci & Ind Res, Lucknow 226001, Uttar Pradesh, India
关键词
Pyranocoumarins; Anti-hyperglycemic; Anti-dyslipidemic; PTP; 1B; TYROSINE-PHOSPHATASE; 1B; IN-VITRO; INHIBITORS;
D O I
10.1016/j.bmcl.2009.09.031
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of pyranocoumarin derivatives were synthesized and evaluated in vivo for their anti-hyperglycemic as well as anti-dyslipidemic activities. Compounds 7a, 7c, 8a, 8b, 8c, 8e and 8f have shown promising anti-hyperglycemic activities in sucrose loaded model (SLM) as well as sucrose challenged streptozotocin induced diabetic rat model (STZ). Compounds 8a and 8b were showing 38.0% and 42.0% blood glucose lowering activity in db/db mice model. In vitro anti-hyperglycemic activity evaluation exhibited that compounds 8a (IC50 = 24.5 mu M) and 8b (IC50 = 36.2 mu M) are potential PTP-1B inhibitors thereby revealing their possible mechanism of anti-diabetic action. Compounds 7a, 7b, 8a, 8b, 8d, 8e and 8f have shown significant anti-dyslipidemic activity in triton induced dyslipidemia in rats. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6447 / 6451
页数:5
相关论文
共 17 条
[1]   Protein tyrosine phosphatase 1B inhibitors from Morus root bark [J].
Cui, L ;
Na, MK ;
Oh, M ;
Bae, EY ;
Jeong, DG ;
Ryu, SE ;
Kim, S ;
Kim, BY ;
Oh, WK ;
Ahn, JS .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (05) :1426-1429
[2]  
Das Ani V., 1996, Indian Journal of Experimental Biology, V34, P341
[3]   Mode of action and adverse effects of lipid lowering drugs [J].
Eghdamian, B ;
Ghose, K .
DRUGS OF TODAY, 1998, 34 (11) :943-956
[4]   A tailored therapy for the metabolic syndrome -: The dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models [J].
Etgen, GJ ;
Oldham, BA ;
Johnson, WT ;
Broderick, CL ;
Montrose, CR ;
Brozinick, JT ;
Misener, EA ;
Bean, JS ;
Bensch, WR ;
Brooks, DA ;
Shuker, AJ ;
Rito, CJ ;
McCarthy, JR ;
Ardecky, RJ ;
Tyhonas, JS ;
Dana, SL ;
Bilakovics, JM ;
Paterniti, JR ;
Ogilvie, KM ;
Liu, S ;
Kauffman, RF .
DIABETES, 2002, 51 (04) :1083-1087
[5]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422
[6]   Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B - Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein [J].
Goldstein, BJ ;
Bittner-Kowalczyk, A ;
White, MF ;
Harbeck, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (06) :4283-4289
[7]   SPECIFIC ASSAYS OF SOME PHOSPHATASES IN SUBCELLULAR FRACTIONS OF SMALL INTESTINAL MUCOSA [J].
HUBSCHER, G ;
WEST, GR .
NATURE, 1965, 205 (4973) :799-&
[8]   GLOBAL ESTIMATES FOR PREVALENCE OF DIABETES-MELLITUS AND IMPAIRED GLUCOSE-TOLERANCE IN ADULTS [J].
KING, H ;
REWERS, M .
DIABETES CARE, 1993, 16 (01) :157-177
[9]   Alpha-glucosidase inhibitors [J].
Lebovitz, HE .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (03) :539-&
[10]   In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones [J].
Rakowitz, D ;
Maccari, R ;
Ottaná, R ;
Vigorita, MG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (02) :567-574